ExeGi Pharma announces first patient enrollment in the PROF Trial of EXE-346
ROCKVILLE, Md., Dec. 8, 2023 /PRNewswire/ -- ExeGi Pharma, a pioneering biopharmaceutical company dedicated to the development and commercialization of innovative live biotherapeutics, has announced the first patient enrollment in its landmark PROF Trial. The trial will study the potential of EXE-346, a novel live biotherapeutic, as treatment for excessive stool frequency in patients with an ileal pouch-anal anastomosis. Live biotherapeutics are similar to probiotics in that they contain live beneficial bacteria, however live biotherapeutics as therapeutic drug products require FDA approval.